Business
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosisNo FDA-approved treatment exists for chronic babesiosis, a debilitating illness WASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharm
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"image","alt":"Sixty Degrees Pharmaceuticals","displaySize":"","headline":null,"caption":"Sixty Degrees Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L1lrb.zKykt_bMbAkYncaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"90-day trial measuring change in general fatigue in chronic babesiosis patients","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment expected to commence Q4 2025 and to be completed by Q2 2026","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Site has clinical expertise in infectious disease trials and access to a robust patient population with tick-borne illness, including chronic babesiosis","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"No FDA-approved treatment exists for chronic babesiosis, a debilitating illness","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":380,"olType":false},{"type":"text","content":"WASHINGTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today it has signed a clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York City as the central site for a Phase II clinical study of tafenoquine in treating chronic babesiosis.","length":447,"tagName":"p"},{"type":"text","content":"For the purposes of the study, chronic babesiosis is defined as a patient with disabling fatigue of at least six months duration, with other symptoms, and laboratory confirmation of, babesiosis.","length":194,"tagName":"p"},{"type":"text","content":"The open-label study (NCT06656351) will evaluate the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days, treating patients with a presumptive diagnosis of chronic babesiosis. The primary endpoint will be resolution of fatigue assessed using a patient reported outcome measure (the multi-dimensional fatigue inventory ...